{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["211(6)"],"submitter":["Smith JA"],"funding":["Bellus Health, a GSK company"],"pubmed_abstract":["<b>Rationale:</b> There is no broadly accessible treatment for patients with refractory chronic cough, a disease characterized by chronic cough that persists despite treatment for other cough-related etiologies or has no identified underlying cause. <b>Objectives:</b> SOOTHE (NCT04678206), a phase 2b, randomized, placebo-controlled trial, evaluated the efficacy and safety of P2X3 antagonist camlipixant in adults with refractory chronic cough (cough duration, ⩾1 yr; baseline awake cough frequency, ⩾25 coughs/h). <b>Methods:</b> After a single-blind, 16-day placebo run-in, patients were randomized (1:1:1:1) to receive camlipixant 12.5, 50, or 200 mg twice daily or placebo for 4 weeks. The primary endpoint was change from baseline to Day 28 in objective 24-hour cough frequency. Secondary endp"],"journal":["American journal of respiratory and critical care medicine"],"pagination":["1038-1048"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12180140"],"repository":["biostudies-literature"],"pubmed_title":["Camlipixant in Refractory Chronic Cough: A Phase 2b, Randomized, Placebo-controlled Trial (SOOTHE)."],"pmcid":["PMC12180140"],"pubmed_authors":["McGarvey L","Morice AH","Bonuccelli CM","Birring SS","Blaiss MS","Garin M","Sher M","Yang R","Smith JA","Lanouette S","Shaw J","Carroll KJ"],"additional_accession":[]},"is_claimable":false,"name":"Camlipixant in Refractory Chronic Cough: A Phase 2b, Randomized, Placebo-controlled Trial (SOOTHE).","description":"<b>Rationale:</b> There is no broadly accessible treatment for patients with refractory chronic cough, a disease characterized by chronic cough that persists despite treatment for other cough-related etiologies or has no identified underlying cause. <b>Objectives:</b> SOOTHE (NCT04678206), a phase 2b, randomized, placebo-controlled trial, evaluated the efficacy and safety of P2X3 antagonist camlipixant in adults with refractory chronic cough (cough duration, ⩾1 yr; baseline awake cough frequency, ⩾25 coughs/h). <b>Methods:</b> After a single-blind, 16-day placebo run-in, patients were randomized (1:1:1:1) to receive camlipixant 12.5, 50, or 200 mg twice daily or placebo for 4 weeks. The primary endpoint was change from baseline to Day 28 in objective 24-hour cough frequency. Secondary endp","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jun","modification":"2026-06-03T07:46:52.284Z","creation":"2026-04-26T03:10:07.602Z"},"accession":"S-EPMC12180140","cross_references":{"pubmed":["40043302"],"doi":["10.1164/rccm.202409-1752OC"]}}